Uricosuric Effect of Fenofibrate in Healthy Volunteers

Publisher Website
Google Scholar
Abstract
The uricosuric properties of a single oral dose (300 mg) of fenofibrate, or isopropyl-[4''-(p-chlorobenzoyl)-2-phenoxy-2-methyl]propionate (LF 178), a new hypolipidemic drug, was investigated vs. placebo, benzbromarone, with and without urine alkalinization, in 10 normouricemic male volunteers, following a crossover design. Increased 2-fold uric acid clearance values were obtained after fenofibrate and 4-fold increased values after benzbromarone. The ratio urinary uric acid/urinary creatinine (UUA/UCr) was enhanced after fenofibrate and benzbromarone vs. placebo. The urine alkalinization with fenofibrate intake increased this ratio to a higher extent.

This publication has 6 references indexed in Scilit: